{"id":11116,"date":"2025-01-01T23:24:15","date_gmt":"2025-01-01T22:24:15","guid":{"rendered":"http:\/\/www.lasalmasgroup.com\/effektive-ketamintherapie-bei-depressionen-in-spanien\/"},"modified":"2026-04-06T18:20:41","modified_gmt":"2026-04-06T16:20:41","slug":"effective-ketamine-therapy-for-depression-in-spain","status":"publish","type":"post","link":"https:\/\/www.lasalmasgroup.com\/en\/effective-ketamine-therapy-for-depression-in-spain\/","title":{"rendered":"Effective ketamine therapy for depression at Las Almas"},"content":{"rendered":"

Psychedelisch-assistierte Therapiee therapy: An innovative approach in the treatment of affective and stress-related disorders<\/h1>\r\n

Introduction<\/strong><\/h3>\r\n

In recent years, ketamine therapy has established itself as a promising intervention method for the treatment of affective disorders and stress-related illnesses. Las Almas Institutes in Vienna and Mallorca<\/strong> Psychedelisch-assistierte Therapiee is used as part of an integrative therapy approach to treat major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), anxiety disorders, and substance use disorders. The innovative combination of ketamine infusions with neuroscientifically based therapeutic approaches enables significant clinical improvements, especially in treatment-resistant cases.<\/p>\r\n

\r\n

Pharmacological action of ketamine<\/strong><\/h3>\r\n

Psychedelisch-assistierte Therapiee, a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, was originally developed as an anesthetic and has been used in medicine for several decades. Recently, the drug's antidepressant effects have become the focus of research. Studies show that ketamine enhances glutamatergic neurotransmission by blocking NMDA receptors, leading to increased synaptic plasticity (Zarate et al., 2006).<\/p>\r\n

Furthermore, ketamine is thought to promote the expression of brain-derived neurotrophic factor (BDNF), thus exerting neuroprotective effects (Autry & Monteggia, 2012). This mechanism contrasts with conventional antidepressants, which target monoaminergic systems and have a significantly longer latency to onset of action.<\/p>\r\n

\r\n

Psychedelisch-assistierte Therapiee therapy for depression<\/strong><\/h3>\r\n

Treatment-resistant depression (TRD)<\/strong><\/h4>\r\n

The treatment of treatment-resistant depression presents a particular challenge in psychiatry. Traditional drug approaches show insufficient effects in approximately 30% of patients (Rush et al., 2006). Psychedelisch-assistierte Therapiee has proven to be an effective treatment alternative: Just a few hours after the first infusion, patients report a significant reduction in depressive symptoms, including suicidal thoughts (Diazgranados et al., 2010). This rapid antidepressant effect is unique and can be life-saving, especially in acute crisis situations.<\/p>\r\n

In the Las Almas Institutes<\/strong>\u00a0Psychedelisch-assistierte Therapiee therapy is complemented by several treatment approaches:<\/p>\r\n